Vintage Labs cited for inadequate investigation of microbiological contamination
This article was originally published in The Gold Sheet
Executive SummaryGeneric drug maker Vintage Pharmaceuticals of Huntsville, Ala., received a Feb. 1 warning letter from FDA for not adequately investigating evidence of microbiological contamination and failure to maintain a complete record of data in the course of each test, as well as failing to follow appropriate written procedures designed to prevent objectionable microorganisms in drug product. The letter stated that "the inspection initially found your firm had over 13 months of environmental monitoring data. There was no record showing isolates obtained from air samples were being identified; and, during the inspection, our investigators were told there was no record of environmental trending data.
You may also be interested in...
Roche receives initial knockback for lymphoma treatment which could rival CAR-T therapies.
Parliamentary debate next week on the post-Brexit regulatory adjustments ahead for the UK medical devices industry will coincide with the opening of post-Brexit EU trade talks by the UK government. After a period of nervous calm, Brexit will be back with a bang.
Europe’s Innovative Medicines Initiative is to get €90m in funding for programs targeting the coronavirus outbreak.